oleclumab + durvalumab + mFOLFOX

**oleclumab + durvalumab + mFOLFOX** is a multi-agent investigational combination therapy used in clinical trials for metastatic colorectal cancer and other solid tumors. The regimen includes oleclumab (a monoclonal antibody targeting CD73), durvalumab (an immune checkpoint inhibitor targeting PD-L1), and modified FOLFOX (a standard chemotherapy protocol containing folinic acid, fluorouracil, and oxaliplatin)[1][2][4][5]. Oleclumab blocks CD73, suppressing tumor adenosine-mediated immune evasion; durvalumab blocks PD-L1, enhancing anti-tumor T-cell activity; mFOLFOX impairs DNA synthesis and causes cytotoxicity in rapidly dividing cells[7]. The combination aims to synergize chemotherapy’s cytotoxic effects with immune-mediated anti-tumor activity.

Brand names

Imfinzi

Other names

anti-CD73 + anti-PD-L1 + modified FOLFOX